Emerging Lipid-Lowering Therapies
Enlicitide plus statins shows positive lipid-lowering effects
Presented by
Prof. Alberico L. Catapano, University of Milan, Italy
Enlicitide, as an add-on therapy to statins, demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) compared with other lipid-lowering therapies in patients with hypercholesterolaemia, according to phase 3 data reported by Prof. Alberico L. Catapano (University of Milan, Italy).
Emerging Lipid-Lowering Therapies
Enlicitide shows sustained lipid lowering in patients with or at risk of ASCVD
Presented by
Prof. Ann Marie Navar, University of Texas Southwestern Medical Center, TX, USA
Enlicitide versus placebo demonstrated significant and sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipids, together with high treatment adherence, according to a pooled analysis of phase 3 trials reported by Prof. Ann Marie Navar (University of Texas Southwestern Medical Center, TX, USA).
Emerging Lipid-Lowering Therapies
Lerodalcibep is effective in reducing LDL-C in high-risk patients on statin therapy
Presented by
Prof. Huo Yong, Peking University First Hospital, China
Lerodalcibep, compared with placebo, led to greater reductions in low-density lipoprotein cholesterol (LDL-C) in Chinese patients with high or very high risk of atherosclerotic vascular disease who had elevated LDL-C levels despite statin therapy, according to a phase 3 trial.
Emerging Lipid-Lowering Therapies
Meta-analysis of clinical trials confirms the efficacy of recaticimab in lipid reduction
Presented by
Dr Sergio Fausto Girón, Francisco Marroquín University, Guatemala
Recaticimab, compared with placebo, leads to significant improvements in low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) across populations at risk of cardiovascular disease, according to a meta-analysis of phase 3 clinical trials.
Established and Investigational Therapies: Efficacy and Safety
Meta-analysis confirms the impact of obicetrapib on atherogenic lipid levels
Presented by
Dr Prutha R. Pathak, North Alabama Medical Center, AL, USA
Obicetrapib, compared with placebo, reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C) and apolipoprotein B (ApoB) levels, while increasing HDL-C levels, according to a systematic review and meta-analysis presented by Dr Prutha R. Pathak (North Alabama Medical Center, AL, USA).
Established and Investigational Therapies: Efficacy and Safety
Obicetrapib shows favourable safety in a pooled analysis of phase 3 trials
Presented by
Dr Adam Nelson, Monash University, Australia
Obicetrapib, compared with placebo, was associated with a lower risk of adverse events related to diabetes, kidney function decline, and liver function, according to a pooled phase 3 analysis presented by Dr Adam Nelson (Monash University, Australia).
Established and Investigational Therapies: Efficacy and Safety
Efficacy of evolocumab confirmed in large meta-analysis
Presented by
Dr Musa Khalil, Howard University Hospital, Washington DC, USA
Evolocumab demonstrates favourable effects on lipid profiles with an overall acceptable safety profile in adults with cardiovascular disease or major risk factors, according to a meta-analysis.
Cardiovascular Outcomes with Lipid-Lowering Strategies
Therapy targeting lower LDL-C levels improves cardiovascular outcomes
Presented by
Prof. Byeong-Keuk Kim, Yonsei University College of Medicine, Republic of Korea
Targeting low-density lipoprotein cholesterol (LDL-C) levels <55 mg/dL is associated with improved cardiovascular outcomes compared with a target of <70 mg/dL in patients with atherosclerotic cardiovascular disease, without an increase in adverse events, according to a report by Prof. Byeong-Keuk Kim (Yonsei University College of Medicine, Republic of Korea).
Cardiovascular Outcomes with Lipid-Lowering Strategies
Evolocumab improves cardiovascular outcomes in patients with high-risk diabetes without significant atherosclerosis
Presented by
Prof. Nicholas Marston, Harvard Medical School, MA, USA
Evolocumab versus placebo significantly improved outcomes for coronary heart disease death, myocardial infarction, and ischaemic stroke in patients with high-risk diabetes and no significant atherosclerosis.
Cardiovascular Outcomes with Lipid-Lowering Strategies
The efficacy of bempedoic acid on cardiovascular outcomes is not impacted by autoimmune or inflammatory disease
Presented by
Dr Bernardo Frison Spiazzi, Cleveland Clinic, OH, USA
Bempedoic acid, compared with placebo, reduced the risk of major adverse cardiovascular events among patients with statin intolerance, regardless of the presence of autoimmune or inflammatory disease.
Precision Risk Stratification and Genetic Profiling
Polygenic risk scores improve coronary artery disease risk prediction alongside LDL
Presented by
Medical student Colin Harper, Broad Institute of MIT and Harvard, MA, USA
Polygenic risk scores (PRS), calculated based on genetic susceptibility variants, have been used to predict the risk of developing coronary artery disease (CAD). Medical student Colin Harper (Broad Institute of MIT and Harvard, MA, USA) presented an analysis evaluating how low-density lipoprotein cholesterol (LDL-C) concentrations can be combined with PRS to refine CAD risk prediction.
Established and Investigational Therapies: Efficacy and Safety
Polygenic scores can identify individuals at risk of an increase in LDL-C over time
Presented by
Dr So Mi Jemma Cho, Massachusetts General Hospital, MA, USA
Genetic risk based on polygenic scores (PGS) for low-density lipoprotein cholesterol (LDL-C) can identify individuals who may benefit from more intensive monitoring and therapeutic management, according to an analysis by Dr So Mi Jemma Cho (Massachusetts General Hospital, MA, USA).